Nivolumab Plus Lenvatinib and Intra-Arterial Locoregional Therapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Real-World Study
Shanzhi Gu, Yang Zhao, Haixiong Yan, Muzi Li, Guowen Li, Manping Huang, Zhengping Xiong, Bin Huang · 2026
Read Nivolumab Plus Lenvatinib and Intra-Arterial Locoregional Therapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Real-World Study by Shanzhi Gu, Yang Zhao, Haixiong Yan, Muzi Li, Guowen Li, Manping Huang, Zhengping Xiong, Bin Huang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13547777.txt.
Description
Shanzhi Gu and seven co-authors test a three-way first cure for liver cancer that cannot be cut out. Their real-world study appeared in twenty twenty-six. The mix joins an immune drug, a targeted drug, and artery-based local care like chemo beads or artery drips. It had shown promise but was not yet standard care.
Fifty-two past patients who got the mix were weighed. Most were men past youth with sound liver work. Tumor shrink hit near seven in ten by one scale, and all had at least held growth. Mid life span came near twenty-five months. Side harms hit most patients, with grave ones in a small share. Wear was the top harm.
Catalog record
| CREATOR | Shanzhi Gu, Yang Zhao, Haixiong Yan, Muzi Li, Guowen Li, Manping Huang, Zhengping Xiong, Bin Huang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |